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The design of cruzipain (CZP) inhibitors, a key protease in the life cycle of the Trypanosoma 
cruzi, the causative agent of Chagas disease, constitutes one of the strategies for the search of 
antichagasic agents. In this context, we have proposed, through docking and MPBSA studies, 
quinoxalinic compounds that could be inhibitors of the enzyme. These compounds were 
designed through its possible interaction in a site (AS2) close to S2 region. This site has been 
indicated as a target for antichagasic drug design.1 Numerous derivatives were synthesized and 
evaluated on endogenous CZP, using as substrate Z-FR-AMC. All the evaluated compounds 
were inactive until concentrations of 10-4 M, but in major concentrations they increased 
considerably the catalytic activity of the enzyme. Although these results did not lead to the 
expected inhibitory effect, they seemed to indicate that the designed compounds interacted 
with the enzyme according to that predicted by the computational studies. In order to shed 
light the experimental results in a molecular approach, we decided to extend the theoretical 
studies using molecular dynamics simulations, to evaluate greater degrees of freedom and 
collective interactions of the system. We studied the behaviour of the enzyme in the absence 
and presence of a quinoxaline derivative, a recognized inhibitor and a substrate. The studies 
carried out, allow us to understand the experimental results, based on structural and 
differential changes of the enzyme in different points of the active site, for each type of 
compound tested. These changes compromise the geometry of the catalytic site. In the 
particular case of quinoxaline, the conformation of the enzyme stabilized is similar as that in 
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